PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Azacitidine

Drugs in development · updated 30 October 2026

Azacitidine: clinical trials and development status

Other names and codes: Onureg, Vidaza

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 17 December 2008

As of 30 October 2026 Azacitidine is in 255 active clinical trials (recruiting or ongoing, phases I–III) for 64 diseases. The most advanced phase is III.

255Active trials
IIIMost advanced phase
64Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Azacitidine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 64 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII161NCT07478991
Myelodysplastic SyndromesIII45NCT06465953
Chronic myelomonocytic leukemiaIII21NCT06647862
LeukemiaIII14NCT07007312
Peripheral T-cell lymphomaII–III9NCT07389616
Hematologic neoplasmIII8NCT07007312
Refractory anemia with excess of blastsII–III5NCT04256317
Chronic lymphocytic leukemiaIII2NCT07082452
Diffuse large B-cell lymphomaII–III2NCT04799275
AnemiaII–III1NCT05469737
Hematologic DiseasesII–III1NCT04256317
Lymphoma, B-Cell, Marginal ZoneII–III1NCT04799275
Patient preferenceIII1NCT05883956
ThrombocytopeniaII–III1NCT05469737
Myeloproliferative disordersII10NCT05564390
Acute biphenotypic leukaemiaII7NCT04128501
Precursor T-cell lymphoblastic leukemiaII6NCT07159620
Residual neoplasmII5NCT06668558
Acute monocytic leukemiaII4NCT00658814
NeoplasmII4NCT07672769
Precursor lymphoblastic lymphoma/leukemiaI–II4NCT07770698
T-cell lymphomaII4NCT04803201
GATA2 deficiencyII3NCT01522976
Myelodysplastic–myeloproliferative diseasesI–II3NCT04140487
Acute erythroid leukemiaII2NCT00658814
Acute megakaryoblastic leukemiaII2NCT00658814
Atypical chronic myeloid leukemiaI–II2NCT06523556
Breast neoplasmII2NCT04891068
Chronic neutrophilic leukemiaI–II2NCT03862157
Enteropathy-associated T-cell lymphomaII2NCT04803201

Everything on Azacitidine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch